PIERI, LISA
PIERI, LISA
Medicina Sperimentale e Clinica
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
2014 F. Lussana;A. Carobbio;M. L. Randi;C. Elena;E. Rumi;G. Finazzi;I. Bertozzi;L. Pieri;M. Ruggeri;F. Palandri;N. Polverelli;E. Elli;A. Tieghi;A. Iurlo;M. Ruella;M. Cazzola;A. Rambaldi;A. M. Vannucchi;T. Barbui
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
2014 Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques
2012 Vannucchi AM; Pieri L; Susini MC; Guglielmelli P
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group
2014 Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group
2014 Paola Guglielmelli; Giada Rotunno;Giada Brogi;Annalisa Pacilli;Costanza Bogani;Carmela Mannarelli;Alessandro Pancrazzi;Rajmonda Fjerza;Lisa Pieri;Elisa Rumi;Daniela Pietra;Federica Delaini;Silvia Salmoiraghi;Aldesia Provenzano; Laura Giunti;Sabrina Giglio;Margherita Maffioli;Alberto Bosi;Alessandro Rambaldi;Tiziano Barbui; Francesco Passamonti; Mario Cazzola and Alessandro Maria Vannucchi
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
2014 Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study.
2014 Martinelli I;De Stefano V;Carobbio A;Randi ML;Santarossa C;Rambaldi A;Finazzi MC;Cervantes F;Arellano-Rodrigo E;Rupoli S;Canafoglia L;Tieghi A;Facchini L;Betti S;Vannucchi AM;Pieri L;Cacciola R;Cacciola E;Cortelezzi A;Iurlo A;Pogliani EM;Elli EM;Spadea A;Barbui T
Chronic myeloproliferative neoplasms: a collaborative approach.
2010 l. Pieri;P. Guglielmelli;A.M. Vannucchi
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
2014 Rumi E;Pietra D;Pascutto C;Guglielmelli P;Martinez-Trillos A;Casetti I;Colomer D;Pieri L;Pratcorona M;Rotunno G;Sant'Antonio E;Bellini M;Cavalloni C;Mannarelli C;Milanesi C;Boveri E;Ferretti V;Astori C;Rosti V;Cervantes F;Barosi G;Vannucchi AM;Cazzola M.
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
2014 Tiziana Storlazzi C;Pieri L;Paoli C;Daniele G;Lasho T;Tefferi A;Vannucchi AM
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.
2013 Klampfl T;Milosevic JD;Puda A;Schönegger A;Bagienski K;Berg T;Harutyunyan AS;Gisslinger B;Rumi E;Malcovati L;Pietra D;Elena C;Della Porta MG;Pieri L;Guglielmelli P;Bock C;Doubek M;Dvorakova D;Suvajdzic N;Tomin D;Tosic N;Racil Z;Steurer M;Pavlovic S;Vannucchi AM;Cazzola M;Gisslinger H;Kralovics R
Concomitant occurrence of BCR-ABL and JAK2V617F mutation.
2011 L. Pieri; A. Spolverini;B. Scappini;U. Occhini;S. Birtolo;A. Bosi;F. Albano;C. Fava;A.M. Vannucchi
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
2023 Sordi, Benedetta; Vanderwert, Fiorenza; Crupi, Francesca; Gesullo, Francesca; Zanotti, Roberta; Bonadonna, Patrizia; Crosera, Lara; Elena, Chiara; Fiorelli, Nicolas; Ferrari, Jacqueline; Grifoni, Federica; Sciumè, Mariarita; Parente, Roberta; Triggiani, Massimo; Palterer, Boaz; Mecheri, Valentina; Almerigogna, Fabio; Santi, Raffaella; Di Medio, Lisa; Brandi, Maria Luisa; Iorno, Maria Loredana; Ciardetti, Isabella; Bencini, Sara; Annunziato, Francesco; Mannarelli, Carmela; Pieri, Lisa; Guglielmelli, Paola; Mannelli, Francesco; Vannucchi, Alessandro M
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
2017 Passamonti, F; Mora, B.; Giorgino, T.; Guglielmelli, P.; Cazzola, M.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; Cervantes, F.; Devos, T.; Palandri, F.; de Stefano, V.; Ruggeri, M.; Silver, R.; Benevolo, G.; Albano, F.; Caramazza, D.; Rumi, E.; Merli, M.; Pietra, D.; Casalone, R.; Barbui, T.; Pieri, L.; Vannucchi, A.M.
Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors
2026 Silvia Linari, Lisa Pieri, Raffaella Pasquino, Eleonora Piellucci, Monica Attanasio, Francesca Salvianti, Giancarlo Castaman
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group
2016 Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution
2021 Carulli, Christian; Innocenti, Matteo; Porciatti, Tommaso; Castellani, Niccolò; Pieri, Lisa; Civinini, Roberto
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
2010 P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
2012 A.Puda;J.D. Milosevic;T. Berg;T. Klampfl;A.S. Harutyunyan;B. Gisslinger;E. Rumi;D. Pietra;L. Malcovati;C. Elena;M. Doubek;M. Steurer;N. Tosic;S. Pavlovic;P. Guglielmelli;L. Pieri;A.M. Vannucchi;H. Gisslinger;M. Cazzola;R. Kralovics.
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
2015 Tapper, William; Jones, Amy V.; Kralovics, Robert; Harutyunyan, Ashot S.; Zoi, Katerina; Leung, William; Godfrey, Anna L.; Guglielmelli, Paola; Callaway, Alison; Ward, Daniel; Aranaz, Paula; White, Helen E.; Waghorn, Katherine; Lin, Feng; Chase, Andrew; Joanna Baxter, E.; Maclean, Cathy; Nangalia, Jyoti; Chen, Edwin; Evans, Paul; Short, Michael; Jack, Andrew; Wallis, Louise; Oscier, David; Duncombe, Andrew S.; Schuh, Anna; Mead, Adam J.; Griffiths, Michael; Ewing, Joanne; Gale, Rosemary E.; Schnittger, Susanne; Haferlach, Torsten; Stegelmann, Frank; Döhner, Konstanze; Grallert, Harald; Strauch, Konstantin; Tanaka, Toshiko; Bandinelli, Stefania; Giannopoulos, Andreas; Pieri, Lisa; Mannarelli, Carmela; Gisslinger, Heinz; Barosi, Giovanni; Cazzola, Mario; Reiter, Andreas; Harrison, Claire; Campbell, Peter; Green, Anthony R.; Vannucchi, Alessandro; Cross, Nicholas C.P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. | 2014 | F. Lussana;A. Carobbio;M. L. Randi;C. Elena;E. Rumi;G. Finazzi;I. Bertozzi;L. Pieri;M. Ruggeri;F. Palandri;N. Polverelli;E. Elli;A. Tieghi;A. Iurlo;M. Ruella;M. Cazzola;A. Rambaldi;A. M. Vannucchi;T. Barbui | |
| A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. | 2014 | Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM | |
| BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques | 2012 | Vannucchi AM; Pieri L; Susini MC; Guglielmelli P | |
| Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group | 2014 | Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am | |
| Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group | 2014 | Paola Guglielmelli; Giada Rotunno;Giada Brogi;Annalisa Pacilli;Costanza Bogani;Carmela Mannarelli;Alessandro Pancrazzi;Rajmonda Fjerza;Lisa Pieri;Elisa Rumi;Daniela Pietra;Federica Delaini;Silvia Salmoiraghi;Aldesia Provenzano; Laura Giunti;Sabrina Giglio;Margherita Maffioli;Alberto Bosi;Alessandro Rambaldi;Tiziano Barbui; Francesco Passamonti; Mario Cazzola and Alessandro Maria Vannucchi | |
| Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. | 2014 | Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P | |
| Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. | 2014 | Martinelli I;De Stefano V;Carobbio A;Randi ML;Santarossa C;Rambaldi A;Finazzi MC;Cervantes F;Arellano-Rodrigo E;Rupoli S;Canafoglia L;Tieghi A;Facchini L;Betti S;Vannucchi AM;Pieri L;Cacciola R;Cacciola E;Cortelezzi A;Iurlo A;Pogliani EM;Elli EM;Spadea A;Barbui T | |
| Chronic myeloproliferative neoplasms: a collaborative approach. | 2010 | l. Pieri;P. Guglielmelli;A.M. Vannucchi | |
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. | 2014 | Rumi E;Pietra D;Pascutto C;Guglielmelli P;Martinez-Trillos A;Casetti I;Colomer D;Pieri L;Pratcorona M;Rotunno G;Sant'Antonio E;Bellini M;Cavalloni C;Mannarelli C;Milanesi C;Boveri E;Ferretti V;Astori C;Rosti V;Cervantes F;Barosi G;Vannucchi AM;Cazzola M. | |
| Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. | 2014 | Tiziana Storlazzi C;Pieri L;Paoli C;Daniele G;Lasho T;Tefferi A;Vannucchi AM | |
| Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. | 2013 | Klampfl T;Milosevic JD;Puda A;Schönegger A;Bagienski K;Berg T;Harutyunyan AS;Gisslinger B;Rumi E;Malcovati L;Pietra D;Elena C;Della Porta MG;Pieri L;Guglielmelli P;Bock C;Doubek M;Dvorakova D;Suvajdzic N;Tomin D;Tosic N;Racil Z;Steurer M;Pavlovic S;Vannucchi AM;Cazzola M;Gisslinger H;Kralovics R | |
| Concomitant occurrence of BCR-ABL and JAK2V617F mutation. | 2011 | L. Pieri; A. Spolverini;B. Scappini;U. Occhini;S. Birtolo;A. Bosi;F. Albano;C. Fava;A.M. Vannucchi | |
| Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis | 2023 | Sordi, Benedetta; Vanderwert, Fiorenza; Crupi, Francesca; Gesullo, Francesca; Zanotti, Roberta; Bonadonna, Patrizia; Crosera, Lara; Elena, Chiara; Fiorelli, Nicolas; Ferrari, Jacqueline; Grifoni, Federica; Sciumè, Mariarita; Parente, Roberta; Triggiani, Massimo; Palterer, Boaz; Mecheri, Valentina; Almerigogna, Fabio; Santi, Raffaella; Di Medio, Lisa; Brandi, Maria Luisa; Iorno, Maria Loredana; Ciardetti, Isabella; Bencini, Sara; Annunziato, Francesco; Mannarelli, Carmela; Pieri, Lisa; Guglielmelli, Paola; Mannelli, Francesco; Vannucchi, Alessandro M | |
| Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients | 2017 | Passamonti, F; Mora, B.; Giorgino, T.; Guglielmelli, P.; Cazzola, M.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; Cervantes, F.; Devos, T.; Palandri, F.; de Stefano, V.; Ruggeri, M.; Silver, R.; Benevolo, G.; Albano, F.; Caramazza, D.; Rumi, E.; Merli, M.; Pietra, D.; Casalone, R.; Barbui, T.; Pieri, L.; Vannucchi, A.M. | |
| Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors | 2026 | Silvia Linari, Lisa Pieri, Raffaella Pasquino, Eleonora Piellucci, Monica Attanasio, Francesca Salvianti, Giancarlo Castaman | |
| Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group | 2016 | Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola | |
| Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution | 2021 | Carulli, Christian; Innocenti, Matteo; Porciatti, Tommaso; Castellani, Niccolò; Pieri, Lisa; Civinini, Roberto | |
| Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. | 2010 | P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi | |
| Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. | 2012 | A.Puda;J.D. Milosevic;T. Berg;T. Klampfl;A.S. Harutyunyan;B. Gisslinger;E. Rumi;D. Pietra;L. Malcovati;C. Elena;M. Doubek;M. Steurer;N. Tosic;S. Pavlovic;P. Guglielmelli;L. Pieri;A.M. Vannucchi;H. Gisslinger;M. Cazzola;R. Kralovics. | |
| Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms | 2015 | Tapper, William; Jones, Amy V.; Kralovics, Robert; Harutyunyan, Ashot S.; Zoi, Katerina; Leung, William; Godfrey, Anna L.; Guglielmelli, Paola; Callaway, Alison; Ward, Daniel; Aranaz, Paula; White, Helen E.; Waghorn, Katherine; Lin, Feng; Chase, Andrew; Joanna Baxter, E.; Maclean, Cathy; Nangalia, Jyoti; Chen, Edwin; Evans, Paul; Short, Michael; Jack, Andrew; Wallis, Louise; Oscier, David; Duncombe, Andrew S.; Schuh, Anna; Mead, Adam J.; Griffiths, Michael; Ewing, Joanne; Gale, Rosemary E.; Schnittger, Susanne; Haferlach, Torsten; Stegelmann, Frank; Döhner, Konstanze; Grallert, Harald; Strauch, Konstantin; Tanaka, Toshiko; Bandinelli, Stefania; Giannopoulos, Andreas; Pieri, Lisa; Mannarelli, Carmela; Gisslinger, Heinz; Barosi, Giovanni; Cazzola, Mario; Reiter, Andreas; Harrison, Claire; Campbell, Peter; Green, Anthony R.; Vannucchi, Alessandro; Cross, Nicholas C.P. |